Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.

This study demonstrates that compared with chemotherapy, PD-1 inhibitor may result in a higher risk of immune-related pneumonitis. Nivolumab plus ipilimumab therapy had the highest pneumonitis risk. These findings could be taken into account by the physicians in decision making.